Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LAURION Intercepts of 37.70 g/t Gold over 0.50 m, 6.60 g/t Gold over 1.00 m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bausch Lomb Ord Shs T.BLCO

Alternate Symbol(s):  BLCO

Healthcare Medical Devices
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative... see more

Recent & Breaking News (TSX:BLCO)

Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®

Business Wire September 6, 2023

Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting

Business Wire September 6, 2023

Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference

Business Wire August 29, 2023

Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®

Business Wire August 24, 2023

Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook

Business Wire August 2, 2023

Bausch + Lomb Solidifies Leadership Team

Business Wire August 1, 2023

Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2

Business Wire July 11, 2023

Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops

Business Wire July 6, 2023

Bausch Health's Bausch + Lomb to Acquire Novartis' XIIDRA(R)

Accesswire June 30, 2023

Bausch + Lomb Will Acquire XIIDRA®

Business Wire June 30, 2023

Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States

Business Wire June 12, 2023

Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting

Business Wire June 8, 2023

Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States

Business Wire June 6, 2023

Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States

Business Wire June 5, 2023

Bausch + Lomb Announces Key Leadership Changes

Business Wire June 1, 2023

Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO(TM) (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease

Business Wire May 18, 2023

Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance

Business Wire May 3, 2023

Bausch + Lomb Releases Annual Environmental, Social and Governance Report

Business Wire May 1, 2023

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Business Wire April 26, 2023

Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results

Business Wire April 25, 2023